PO No :PO1931200801-436

Name : Ms.MRS.ASHRAF BEGUN :

Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548856 / 6175217 Sample Receive Date : 30/Nov/2022 11:51AM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 30/Nov/2022 03:01PM

HAEMATOLOGY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Glycosylated Hemoglobin (HbA1c) 11.7 % 4-5.6 HPLC

Estimated average glucose (eAG) 289.09 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

Page 1 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548856 / 6175217 Sample Receive Date : 30/Nov/2022 11:51AM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 30/Nov/2022 02:23PM

HAEMATOLOGY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 7.6 g/dL 12.0 - 15.0 Cyanide-free SLS-
Hemoglobin
RBC 3.55 10^6/cu.mm 3.8-4.8 DC Impedence Method
HCT 24.6 % 36-46 Pulse height average
MCV 69.3 fl 83 - 101 Calculated
MCH 21.3 pg 27 - 32 Calculated
MCHC 30.8 g/dL 31.5 - 34.5 Calculated
RDW-CV 19.3 % 11.5-14 Calculated
Total Leucocyte Count 6.36 10^3/µI 4 - 10 Flowcytometry/Microscopy
Differential Leucocyte Count
Neutrophils 53.4 % 40-80 Flowcytometry/Microscopy
Lymphocytes 28.5 % 20-40 Flowcytometry/Microscopy
Monocytes 10.4 % 2-10 Flowcytometry/Microscopy
Eosinophils 7.1 % 1-6 Flowcytometry/Microscopy
Basophils 0.6 % 0-2 Flowcytometry/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 3.4 10^3/µI 2-7 Calculated
Absolute Lymphocyte Count 1.81 10^3/µI 1-3 Calculated
Absolute Monocyte Count 0.66 10^3/µI 0.2-1 Calculated
Absolute Eosinophil Count 0.45 10^3/µI 0.02-0.5 Calculated
Absolute Basophil Count 0.04 10^3/µI 0.02-0.1 Calculated
Platelet Count 420 10^3/µI 150-410 Electrical Impedence
MPV 8.2 fl 6.5 - 12 Calculated
PDW 15 fL 11-20 Calculated
NOTE : Microcytic hypochromic anemia ;Rule out iron deficiency anemia

Comment:

Page 2 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548856 / 6175217 Sample Receive Date : 30/Nov/2022 11:51AM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 30/Nov/2022 02:23PM

HAEMATOLOGY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts
are additionally being reported as absolute numbers of each cell in per unit volume of blood.
Test conducted on EDTA whole blood.

Page 3 of 14
 PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548853 / 6175217 Sample Receive Date : 30/Nov/2022 12:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : FLUORIDE PLASMA Report Date : 30/Nov/2022 01:58PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Glucose - Fasting
Glucose - Fasting 433 mg/dL 70.0 - 99.0 Hexokinase

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c

Page 4 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 05:04PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 124 mg/dL Low (desirable): < 200 Enzymatic
mg/dL
Moderate (borderline)
200–239 mg/dL
High: = 240 mg/dL
Triglycerides 381 mg/dL Normal: < 150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200 - 499, Very
High >=500
Cholesterol - HDL 27 mg/dL Low (undesirable, high Elimination/catalase
risk): < 40 mg/dL
High (desirable, low risk):
>= 60 mg/dL
Cholesterol - LDL 21 mg/dL Desirable: <100 Elimination/catalase
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 76 mg/dL 10-30 Calculated
Cholesterol : HDL Cholesterol 4.6
LDL : HDL Cholesterol 0.76
Non HDL Cholesterol 97

Comment:

Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart
are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

Page 5 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 05:04PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic
Cardiovascular Disease (ASCVD) risk factors, especially lipid profile. This should be done earlier if there is a family
history of premature heart disease, dyslipidemia, obesity, or other risk factors.
The LAI recommends LDL-C as the primary target and non-HDL-C as a co-primary target, for lipid-lowering therapy.
Non-HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL
remnants, Chylomicron remnants and Lp(a).
Apo B measurement is recommended in high-risk subjects after LDL-C and non-HDL-C goals have been achieved.
Additional testing for Apolipoprotein B, hsCRP, Lp(a ) and LP-PLA2 should be considered among patients with
moderate risk for ASCVD for risk refinement.

Updated 2020 risk stratification approach recommended by the Lipid Association of India

Risk Factors/Markers
Moderate-risk
Major ASCVD Risk Factors Other High risk features nonconventional risk
factors
1. Age ≥45 years in males and 1. Diabetes with 0-1 other major ASCVD Risk factors and no 1. Coronary calcium score
≥55 years in females evidence of target organ damage 100-299
2. Family history of premature
2. CKD Stage 3B or 4 2. Increased carotid IMT
ASCVD
3. Current cigarette smoking and 3. Familial hypercholesterolemia (other than familial 3. Lipoprotein (a) 20-49
tobacco use homozygous hypercholesterolemia mg/dL
4. High blood pressure 4. Extreme of a single risk factor 4. Impaired Fasting Glucose*
5. Increased waist
5. Low HDL-C 5. Coronary calcium score ≥300
circumference**
6. Apolipoprotein B ≥110
6. Non-stenotic carotid plaque
mg/dL
7. Lipoprotein (a) ≥50 mg/dL 7. hsCRP ≥2 mg/L***

Risk groups
Low risk Moderate risk High risk Very High risk Extremely High risk
2 Major
≥3 major ASCVD
ASCVD risk Pre-existing ASCVD Category A Category B
risk factor
factors
0-1 major
Low risk group 2 major ASCVD risk
ASCVD risk Diabetes ≥2 other CAD ≥1 feature of very high risk
≥1 moderate- factor with ≥1
factor and major risk factors or group or recurrent ACS (within
risk moderate-risk
Lifetime CVD evidence of target one year) despite LDL-C ≤50
nonconventional nonconventional risk
risk <30% organ damage mg/dL or polyvascular disease
risk factors factors
Lifetime CVD ≥1 other high risk Familial homozygous
risk ≥30% features Hypercholesterolemia

Page 6 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 05:04PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

* A fasting blood sugar level from 100 to 125 mg/dl. It should be confirmed by repeat testing; **Waist circumference is to be
measured at the superior border of the iliac crest just after expiration. Increased waist circumference is defined as >90 cm
in men and >80 cm in women. If increased waist circumference is the only risk factor, it should again be measured after 6
months after initiating heart-healthy lifestyle measures; ***On two occasions at least 2 weeks apart. For reclassifying moderate
risk group only.
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020
Risk groups Treatment Goals Consider Drug Therapy
LDL-C (mg/dL) Non-HDL (mg/dL) LDL-C (mg/dL) Non-HDL (mg/dL)
Extreme Risk Group Category A <50 (Optional goal ≤30) <80 (Optional goal ≤60) ≥50 ≥80
Extreme Risk Group Category B ≤30 ≤60 >30 >60
Very High Risk <50 <80 ≥50 ≥80
High Risk <70 <100 ≥70 ≥100
Moderate Risk <100 ≥100 ≥130
Low risk <100 ≥130* ≥160*
*After an adequate non-pharmacological intervention for at least 3 months

Page 7 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 05:04PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Liver Function Test

Bilirubin-Total 0.31 mg/dL 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.12 mg/dL 0.0-0.3 Vanadate oxidation
Bilirubin-Indirect 0.19 mg/dL 0.1 - 1.0 Calculated
Protein, Total 7.25 g/dL 5.7 - 8.2 Biuret
Albumin 3.94 g/dL 3.4 - 4.8 BCG Dye Binding
Globulin 3.3 g/dl 1.8-3.6 Calculated
A/G Ratio 1.19 Ratio Calculated
Aspartate Transaminase (SGOT) 32 U/L <34 U/L Modified IFCC
Alanine Transaminase (SGPT) 52 U/L 10-49 Modified IFCC
SGOT/SGPT 0.62 Ratio Calculated
Alkaline Phosphatase 108 U/L 46-116 IFCC Standardization
Gamma Glutamyltransferase (GGT) 32 U/L <38 Modified IFCC

Comment:

LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of
the Existence, Extent and Type of Liver damage. - Acute Hepatocellular damage: ALT & AST levels are sensitive index of
hepatocellular damage - Obstruction to the biliary tract,Cholestasis and blockage of bile flow:1) Serum Total Bilirubin
concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-
Nucleotidase - Chronic liver disease: Serum Albumin concentration
Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous
membranes caused by hyperbilirubinemia.
Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s
syndrome, Crigler-Najjar syndrome
Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT
concentrations are elevated even before the clinical signs and symptoms of disease appear.
ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity.

Page 8 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 05:04PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease,
reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with
worsening of the patient's condition.
Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper
reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade
of fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after
administration of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3)
autoimmune hepatitis, (4) primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency.
AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching
concentrations up to eight times the upper reference limit.Slight to moderate AST elevations are noted in hemolytic
disease.
GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease
regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant
drugs, such as phenytoin and phenobarbital.

Page 9 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 06:16PM

BIOCHEMISTRY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Kidney Function Test.

Blood Urea Nitrogen 16 mg/dL 9.0-21.0 Urease with GLDH
Urea 33.81 mg/dL 19.26-49.22 Calculated
Creatinine 1.20 mg/dL 0.5 - 1.1 Alkaline picrate-kinetic
Uric Acid 3.6 mg/dL 3.1-7.8 Uricase/Peroxidase
Sodium 128 mEq/L 132.0-146.0 Indirect ISE
Potassium 4.39 mEq/L 3.5 - 5.5 Indirect ISE
Chloride 99.4 mEq/L 99.0-109.0 Indirect ISE
BUN/Creatinine Ratio 13.2 Ratio Calculated

Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.

Page 10 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 02:11PM

Immunology
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Thyroid Profile
T3, Total 0.79 ng/mL 0.60 - 1.81 CLIA
T4, Total 9.4 µg/dl 5.5 - 10.8 CLIA
Thyroid Stimulating Hormone - Ultra 5.788 uIU/ml 0.55 - 4.78 CLIA
Sensitive

Comment:

Below mentioned are the guidelines for pregnancy related reference ranges for TSH, total T3 & Total T4.

Pregnancy
TSH (μIU/mL) (as per
American Thyroid Total T3 (ng/mL) Total T4(μg/dL)
Association )
1st trimester 0.1-2.5 0.81-1.90 7.33-14.8
2nd trimester 0.2-3.0 1.00-2.60 7.93-16.1
3rd trimester 0.3-3.0 1.00-2.60 6.95-15.7

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Total T3 & T4 concentrations are altered by physiological or pathological changes in thyroxine binding globulin (TBG)
capacity .
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
For diagnostic purposes, results should be used in conjunction with other data.

Page 11 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548855 / 6175217 Sample Receive Date : 30/Nov/2022 12:05PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 30/Nov/2022 02:11PM

Immunology
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism

Page 12 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548854 / 6175217 Sample Receive Date : 30/Nov/2022 11:48AM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 30/Nov/2022 12:50PM

CLINICAL PATHOLOGY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

Urine Routine & Microscopy

Colour YELLOW Pale Yellow Manual
Appearance CLEAR Clear Manual
Specific gravity 1.00500 1.003 - 1.035 pKa change
pH 6.0 4.6 - 8.0 Double Indicator
Glucose POSITIVE (+++) Negative GOD-POD
Protein NEGATIVE Negative Protein Error Principle
Ketones NEGATIVE Negative Nitroprusside
Blood NEGATIVE Negative Peroxidase
Bilirubin NEGATIVE Negative Diazonium
Urobilinogen NORMAL Normal Ehrlich
Leucocyte Esterase NEGATIVE Negative Pyrrole
Nitrite NEGATIVE Negative P-arsanilic acid
Pus cells 2-3 /hpf 0-5 Microscopy
Red Blood Cells NIL /hpf 0-2 Microscopy
Epithelial cells 2-4 /hpf Few Microscopy
Casts NIL Nil Microscopy
Crystals NIL Nil Microscopy
Yeast NIL Nil Microscopy
Bacteria NIL Nil Microscopy

Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens

Page 13 of 14
PO No :PO1931200801-436
Name : Ms.MRS.ASHRAF BEGUN :
Age/Gender : 47/Female Registration Date : 30-Nov-22 11:08 AM
Patient ID : HYD112416 Collection Date : 30/Nov/2022 08:56AM
Barcode ID / Order ID : D0548854 / 6175217 Sample Receive Date : 30/Nov/2022 11:48AM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 30/Nov/2022 12:50PM

CLINICAL PATHOLOGY
GOOD HEALTH GOLD PACKAGE
Test Name Result Unit Bio. Ref. Interval Method

*** End Of Report ***

Page 14 of 14
Thank you for choosing us as your healthcare partner
Tata 1mg Labs, India’s trusted diagnostics lab chain, has a nationwide network of 9
diagnostics labs, serving over a million customers each year across 35 cities. Equipped
with the latest technologies, our diagnostics chain brings home to you an extensive
catalog of tests.

20 Lakh+ Detailed Accurate & Sample collection by

satisfied customers information of timely reports vaccinated & certified
each test professionals

What makes us India’s trusted diagnostic services?

1. All samples are processed under the

supervision of highly qualified Pathologists,
Microbiologists, Biochemists and Molecular
Scientists. Our labs are operated by a team
of expert medical professionals with a
collective experience of 200+ years.

2. We ensure that all tests are carried out with

utmost care, in accordance with the
accepted national and international norms
and clinical safety standards such as good
laboratory practices by WHO and ICMR.

3.
“
Our lab test reports undergo multiple levels
of meticulous processing and detailed
verification. Every single report goes
“
through a 3-step review process and is
verified by a doctor holding a postgraduate
degree in Pathology or Microbiology.

CONFUSED ABOUT YOUR REPORTS?

Now, consult India’s top doctors from the
comfort of your home.

CLAIM YOUR FREE CONSULTATION

Why are regular health checkups important?
Help in early detection of diseases Help cut down any future
& prevent severe complications healthcare cost

Identify underlying stress-related Help monitor overall health of

disease/condition you & your family

Our most booked

preventive health checkups:

Comprehensive Full Body Good Health Silver

Checkup Gold (70+ Tests) Package (50+ Tests)

*Prices are subject to change as per location

CBC, Thyroid Profile, Lipid Profile, CBC, Diabetes Screening, Lipid Profile,
Iron Profile, Vitamin Profile, CRP, Thyroid Profile, Kidney Panel,
Urine Routine Liver Panel

A full body check up that screens you Helps you make better & healthier
for common health conditions related lifestyle choices by giving you an
to thyroid, heart, liver, kidney, bones overview of your health status
and blood

Book now starting at ₹1999* Book now starting at ₹599*

Check out and compare our most

COMPARE HERE
popular packages here
Common symptoms may indicate underlying
health conditions!

What's causing your fever?

Get timely diagnosis with

BOOK NOW
Fever Package Extensive
Tests for Dengue, Malaria, Typhoid & Chikungunya

Feeling tired and fatigued often?

Check your Vitamin D,

BOOK NOW
B12 & B9 levels with
Vitamin Profile

For booking assistance, contact us on

Call: 1800-212-2323 WhatsApp: 9717-719-814

Book your test on 1mg.com/labs

Home sample Free doctor 100% vaccinated Trusted &

collection consultation phlebotomists certified labs

Conditions of Laboratory Testing & Reporting:

*Test results released pertain to the sample,as received *Laboratory investigations are only a tool to facilitate in arriving at
a diagnosis and should be clinically correlated by the interpreting clinician.*Result delays may happen because of
unforeseen or uncontrollable circumstances.*Test report may vary depending on the assay method used *Test results may
show inter-laboratory variations *Test results are not valid for medico-legal purposes *Please mail your queries related to
test results to Customer Care mail ID cs.labs@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked “BOLD” indicate abnormal results i.e., higher or
lower than normal. All lab test results are subject to clinical interpretation by a qualified medical professional. This report
cannot be used for any medico-legal purposes. Partial reproduction of the test results is not permitted. Also, TATA 1mg
Labs is not responsible for any misinterpretation or misuse of the information. The test reports alone may not be conclusive
of the disease/condition, hence clinical correlation is necessary. Reports should be vetted by a qualified doctor only.